Prognostic significance of 18F-FDG PET at diagnosis in patients with soft tissue sarcoma and bone sarcoma; systematic review and meta-analysis

2016 ◽  
Vol 58 ◽  
pp. 104-111 ◽  
Author(s):  
Tadahiko Kubo ◽  
Taisuke Furuta ◽  
Muhammad P. Johan ◽  
Mitsuo Ochi
2015 ◽  
Vol 43 (5) ◽  
pp. 860-870 ◽  
Author(s):  
Elba C. Etchebehere ◽  
Brian P. Hobbs ◽  
Denái R. Milton ◽  
Osama Malawi ◽  
Shreyaskumar Patel ◽  
...  

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Marc G. Stevenson ◽  
Lukas B. Been ◽  
Harald J. Hoekstra ◽  
Albert J. H. Suurmeijer ◽  
Ronald Boellaard ◽  
...  

Cancers ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 790 ◽  
Author(s):  
Christos Sachpekidis ◽  
Ioannis Karampinis ◽  
Jens Jakob ◽  
Bernd Kasper ◽  
Kai Nowak ◽  
...  

The outcome of high-risk soft tissue sarcoma (STS) is poor with radical surgery being the only potentially curative modality. Pazopanib is a multikinase inhibitor approved for the treatment of metastatic STS. Herein, in terms of the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS) trial, we evaluate the potential role of kinetic analysis of fludeoxyglucose F-18 (18F-FDG) data derived from the application of dynamic positron emission tomography/computed tomography (PET/CT) in response assessment to pazopanib of STS patients scheduled for surgical resection. Sixteen STS patients treated with pazopanib as neoadjuvant therapy before surgery were enrolled in the analysis. All patients underwent dynamic PET/CT prior to and after pazopanib treatment. Data analysis consisted of visual (qualitative) analysis of the PET/CT scans, semi-quantitative evaluation based on standardized uptake value (SUV) calculations, and quantitative analysis of the dynamic 18F-FDG PET data, based on two-tissue compartment modeling. Resection specimens were histopathologically assessed and the percentage of regression grade was recorded in 14/16 patients. Time to tumor relapse/progression was also calculated. In the follow-up, 12/16 patients (75%) were alive without relapse, while four patients (25%) relapsed, among them one patient died. Median histopathological regression was 20% (mean 26%, range 5–70%). The studied population was dichotomized using a histopathological regression grade of 20% as cut-off. Based on this threshold, 10/14 patients (71%) showed partial remission (PR), while stable disease (SD) was seen in the rest 4 evaluable patients (29%). Semi-quantitative evaluation showed no statistically significant change in the widely used PET parameters, SUVaverage and SUVmax. On the other hand, 18F-FDG kinetic analysis revealed a significant decrease in the perfusion-related parameter K1, which reflects the carrier-mediated transport of 18F-FDG from plasma to tumor. This decrease can be considered as a marker in response to pazopanib in STS and could be due to the anti-angiogenic effect of the therapeutic agent.


PLoS ONE ◽  
2018 ◽  
Vol 13 (8) ◽  
pp. e0202314 ◽  
Author(s):  
Ji Nie ◽  
Jing Zhang ◽  
Jinsheng Gao ◽  
Linghong Guo ◽  
Hui Zhou ◽  
...  

2019 ◽  
Vol 1 (Supplement_2) ◽  
pp. ii26-ii26
Author(s):  
Motomasa Furuse ◽  
Naosuke Nonoguchi ◽  
Kei Yamada ◽  
Tohru Shiga ◽  
Jean-Damien Combes ◽  
...  

Abstract BACKGROUND It is challenging to discriminate radiation necrosis from tumor progression, especially in malignant glioma. Therefore many radiological imaging studies have been reported. In this study, we performed a systematic review of radiological diagnosis for radiation necrosis and analyzed the best radiological imaging for malignant glioma. METHODS We divided diagnostic approaches into two categories as follows-CT and MRI (conventional radiological imaging studies), and SPECT and PET (nuclear medicine studies). Our librarians conducted a comprehensive systematic search on Pub Med, Cochrane Library, and the Japan Medical Abstract Society up to March 2015. The searching keywords included radiation necrosis, recurrence, imaging modalities such as MRI, diagnosis, and differential. In a meta-analysis, diagnostic odds ratio (DOR) was calculated. A subanalysis was performed, dividing into tumor types, gliomas and metastatic brain tumors. RESULTS Of 188 and 239 records extracted from the database, 20 and 26 studies were included in the meta-analysis after exclusion of case reports and studies with incompatible content and insufficient information. Gd-enhanced MRI exhibited the lowest sensitivity (63%) and DOR (2.2). On the other hand, combined multiple imaging studies including MRS and perfusion image displayed the highest sensitivity (96%) and DOR (5.9). In the subanalysis for glioma, Gd-enhanced MRI and 18F-FDG-PET revealed low DORs (1.7 and 2.3). Conversely, 18F-FET-PET and combined multiple imaging studies showed high DORs (6.8 and 5.9). CONCLUSIONS Gd-enhanced MRI had low diagnostic ability for differentiation of radiation necrosis. In glioma patients, 18F-FDG-PET was not useful to discriminate radiation necrosis from tumor progression. Combined multiparametric imaging including lesional metabolism and blood flow could enhance diagnostic accuracy and be useful to differentiate radiation necrosis from tumor progression even in glioma patients.


2019 ◽  
Vol 40 (6) ◽  
pp. 626-631 ◽  
Author(s):  
Andrea Sambri ◽  
Giuseppe Bianchi ◽  
Alessandra Longhi ◽  
Alberto Righi ◽  
Davide Maria Donati ◽  
...  

2014 ◽  
Vol 132 (3) ◽  
pp. 669-676 ◽  
Author(s):  
Haleh Ghooshkhanei ◽  
Giorgio Treglia ◽  
Golnaz Sabouri ◽  
Rozita Davoodi ◽  
Ramin Sadeghi

Sign in / Sign up

Export Citation Format

Share Document